Guangrong Zheng Selected Research

DT2216

1/2022	BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
1/2022	Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
1/2020	DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
12/2019	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guangrong Zheng Research Topics

Disease

19	Neoplasms (Cancer) 01/2022 - 11/2016
4	Thrombocytopenia (Thrombopenia) 01/2021 - 12/2019
4	Carcinogenesis 11/2020 - 01/2020
4	Tobacco Use Disorder (Nicotine Dependence) 12/2018 - 10/2007
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2022
2	Leukemia 11/2021 - 12/2019
2	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2020
2	T-Cell Lymphoma (Lymphoma, T Cell) 08/2020 - 01/2020
2	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2020
2	Cardiotoxicity 11/2019 - 01/2018
2	Substance-Related Disorders (Drug Abuse) 01/2019 - 02/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Glioma (Gliomas) 01/2022
1	Breast Neoplasms (Breast Cancer) 11/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 04/2020
1	Drug-Related Side Effects and Adverse Reactions 12/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2019
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2019
1	Carcinoma (Carcinomatosis) 01/2018
1	Teratocarcinoma 01/2018
1	Bacterial Infections (Bacterial Infection) 12/2017
1	Pain (Aches) 04/2011

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
10	Proteolysis Targeting ChimeraIBA 01/2022 - 01/2020
8	snake venom protein C activatorIBA 01/2022 - 12/2019
4	DT2216IBA 01/2022 - 12/2019
3	navitoclaxIBA 04/2020 - 12/2019
3	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 04/2011 - 10/2007
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2021
2	Annexin A5IBA 01/2022 - 01/2022
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 04/2020 - 01/2020
2	Apoptosis Regulatory ProteinsIBA 04/2020 - 01/2020
2	LigandsIBA 01/2020 - 01/2019
2	Ligases (Synthetase)IBA 01/2020 - 01/2020
2	Nicotine FDA Link 10/2015 - 10/2007
1	UbiquitinIBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	Sincalide FDA Link 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	sotorasibIBA 01/2022
1	SenotherapeuticsIBA 10/2021
1	MethyltransferasesIBA 11/2020
1	licochalcone AIBA 11/2020
1	Arginine (L-Arginine)FDA Link 11/2020
1	Histone Deacetylases (Histone Deacetylase)IBA 08/2020
1	Pharmaceutical PreparationsIBA 08/2020
1	EnzymesIBA 04/2020
1	Antineoplastic Agents (Antineoplastics)IBA 12/2019
1	Ether (Diethyl Ether)IBA 11/2019
1	N- (1,2- dihydroxylpropyl)- 2,6- di- (4- methoxyphenethyl)piperidineIBA 11/2019
1	Cholinergic Agents (Cholinergics)IBA 01/2019
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2018
1	Histone DemethylasesIBA 01/2018
1	Clarithromycin (Biaxin)FDA LinkGeneric 12/2017
1	Rifampin (Rifampicin)FDA LinkGeneric 12/2017
1	Biological ProductsIBA 11/2016
1	Conotoxins (Conotoxin)IBA 10/2015
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 02/2013
1	Analgesics (Analgesic Drugs)IBA 04/2011
1	Peptides (Polypeptides)IBA 04/2011
1	1- (3- picolinium)- 12- triethylammonium- dodecane dibromideIBA 10/2007

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2019
3	Drug Therapy (Chemotherapy) 10/2021 - 12/2018
1	Immunotherapy 01/2021
1	Radiotherapy 01/2019
1	Oral Administration 01/2018
1	Self Administration (Administration, Self) 10/2015